Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
ANG Lifesciences India Ltd reported a weak set of numbers for Q3 FY26 (quarter ended 31 Dec 2025). Standalone revenue from operations fell to Rs 1,830.21 lakhs from Rs 2,597.05 lakhs in the same quarter last year, a decline of about 29.5% year-on-year. The company posted a standalone loss after tax of Rs 456.50 lakhs for the quarter versus a loss of Rs 44.37 lakhs in Q3 FY25, with EPS of Rs (7.86). For the nine months ended 31 Dec 2025, revenue was Rs 6,880.44 lakhs (vs Rs 7,224.40 lakhs a year ago) and loss after tax was Rs 552.86 lakhs. On a consolidated basis including subsidiary Mansa Print & Publishers, the nine-month loss widened to Rs 970.32 lakhs. Statutory auditors Khurana Sharma & Co. issued an unmodified review opinion on the results.
Sharply weaker Q3 performance with widening losses and steep revenue drop is negative for shareholders, suggesting pricing pressure, demand slowdown, or execution issues in the pharma formulations business. The stock may face pressure given consecutive quarterly losses and margin compression.